Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -4.80 is 80% above its 5-year average of -23.77, near the high end of its 5-year range (-39.30–-4.80).
41.00% above its 12-month average of -8.13.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.80.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
EARNINGS PER SHARE (EPS)
-4.80
EARNINGS PER SHARE (EPS) AVG TTM
-8.13
EARNINGS PER SHARE (EPS) AVG 3Y
-18.81
EARNINGS PER SHARE (EPS) AVG 5Y
-23.77
EARNINGS PER SHARE (EPS) AVG 10Y
-206.39
EARNINGS PER SHARE (EPS) AVG 15Y
-217.57
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+41.00%
CURRENT VS 3Y AVG
+74.48%
CURRENT VS 5Y AVG
+79.81%
CURRENT VS 10Y AVG
+97.67%
CURRENT VS 15Y AVG
+97.79%
CURRENT VS 20Y AVG
N/A
Immunic, Inc.
Market Cap
$110.88M
Earnings Per Share (EPS)
-4.80
TTM Avg
-8.13
3Y Avg
-18.81
5Y Avg
-23.77
Market Cap
$111.33M
Earnings Per Share (EPS)
-3.21
TTM Avg
-1.79
3Y Avg
-1.14
5Y Avg
-1.14
Market Cap
$108.59M
Earnings Per Share (EPS)
-0.74
TTM Avg
-0.44
3Y Avg
-1.32
5Y Avg
-1.80
Market Cap
$107.84M
Earnings Per Share (EPS)
N/A
TTM Avg
-5.70
3Y Avg
-9.83
5Y Avg
-0.70
Market Cap
$109.49M
Earnings Per Share (EPS)
-0.21
TTM Avg
-0.47
3Y Avg
-0.54
5Y Avg
-0.49
Market Cap
$114.42M
Earnings Per Share (EPS)
-0.47
TTM Avg
-0.87
3Y Avg
-1.14
5Y Avg
-0.92
Market Cap
$112.14M
Earnings Per Share (EPS)
-0.99
TTM Avg
-1.38
3Y Avg
-1.93
5Y Avg
-2.07
Market Cap
$115.06M
Earnings Per Share (EPS)
-1.07
TTM Avg
-1.13
3Y Avg
-1.07
5Y Avg
-0.91
Market Cap
$106.38M
Earnings Per Share (EPS)
-0.71
TTM Avg
-0.33
3Y Avg
-0.37
5Y Avg
-0.32
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Immunic, Inc. (IMUX) | $110.88M | -4.80 | -8.13 | -18.81 | -23.77 |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $111.33M | -3.21 | -1.79 | -1.14 | -1.14 |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $108.59M | -0.74 | -0.44 | -1.32 | -1.80 |
| BGM Group Ltd. (BGM)vs › | $107.84M | N/A | -5.70 | -9.83 | -0.70 |
| Apyx Medical Corporation (APYX)vs › | $109.49M | -0.21 | -0.47 | -0.54 | -0.49 |
| Lucid Diagnostics Inc. (LUCD)vs › | $114.42M | -0.47 | -0.87 | -1.14 | -0.92 |
| Foghorn Therapeutics Inc. (FHTX)vs › | $112.14M | -0.99 | -1.38 | -1.93 | -2.07 |
| Coya Therapeutics, Inc. (COYA)vs › | $115.06M | -1.07 | -1.13 | -1.07 | -0.91 |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $106.38M | -0.71 | -0.33 | -0.37 | -0.32 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $106.13M | -6.48 | -4.79 | -7.51 | -13.98 |
Trailing EPS (TTM)
$-4.80
Forward EPS (Est.)
$-3.57
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -6.24 |
| 2024-12-31 | -10.03 |
| 2023-12-31 | -21.12 |
| 2022-12-31 | -37.84 |
| 2021-12-31 | -39.30 |
| 2020-12-31 | -28.10 |
| 2019-12-31 | -45.24 |
| 2017-12-31 | -524.00 |
| 2016-12-31 | -524.00 |
| 2015-12-31 | -828.00 |
| 2014-12-31 | -1416.00 |
| 2013-12-31 | -528.14 |
| 2012-12-31 | -128.50 |
| 2011-12-31 | -107.89 |
